Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ablation assets

This article was originally published in The Gray Sheet

Executive Summary

CryoCath inks $10 mil. deal to acquire Endocare's cardiac-related product manufacturing operations in Irvine, Calif. The sale is subject to Endocare's clearing certain manufacturing and R&D milestones in 2003. Terms include the exclusive licensing of the Surgifrost cryoablation system to CryoCath in exchange for a nine-year descending royalty stream based on net sales. The deal represents the latest move by Endocare to divest non-core assets to concentrate resources on its Cryocare prostate cancer platform (1"The Gray Sheet" April 14, 2003, p. 27). SurgiFrost was developed through a partnership between the two companies and was approved to treat cardiac arrhythmias in February 2002 (2"The Gray Sheet" Feb. 3, 2003, p. 20)...

You may also be interested in...

Endocare To Shed Non-Core Assets, Focus On Cryocare Indications

Endocare is divesting "certain non-core" assets in order to concentrate resources on expanding adoption of its Cryocare prostate cancer platform and pursuit of additional applications

CryoCath Looks To Ice Atrial Fibrillation, Flutter With Cryoablation Therapies

CryoCath aims to place its Freezor cryoablation catheter in 300 centers by year-end, pending PMA approval of the supraventricular tachycardia treatment device

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts